Altimmune Inc. Common Stock

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Semicondct Bull 3X ETF

Direxion Daily FTSE China Bull 3X ETF

Mast Therapeutics, Inc.

GraniteShares 1.5x Long META Daily ETF

Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

GraniteShares 2x Long AMZN Daily ETF

Direxion Daily Financial Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

VS TR 2x Long VIX Futures ETF

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily Small Cap Bear 3X ETF

Direxion Financial Bear 3X Shar

ProShares Ultra VIX Short-Term Futures

GraniteShares 1.5x Short NVDA Daily ETF

Polyrizon Ltd. Ordinary Shares

Classover Holdings Inc. Class B Common Stock

Freight Technologies Inc. Ordinary Shares

IBO (Listing Market - NYSE Amex Network B F)

Cooper-Standard Holdings Inc. Common Stock

Adaptive Biotechnologies Corporation Common Stock

Wolfspeed Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Duolingo Inc. Class A Common Stock

Trupanion Inc. Common Stock

Zoomcar Holdings Inc. Common Stock

Pro-Dex Inc. Common Stock

Block Inc. Class A Common Stock

Nvni Group Limited Ordinary Shares

fuboTV Inc. Common Stock

Hecla Mining Company Common Stock

Cytokinetics Incorporated Common Stock

Huntsman Corporation Common Stock

Atlassian Corporation Class A Common Stock

Autonomix Medical Inc. Common Stock

Click here to get full coverage on Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (IDYA) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences - Stock Titan

IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences  Stock Titan

IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences - Stock Titan

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025  Yahoo Finance

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Yahoo Finance

Click here to get full coverage on IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire - Stock Titan

IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire  Stock Titan

IDEAYA Awards $306K Worth of Stock Options to Strategic New Hire - Stock Titan

Click here to get full coverage on Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - Yahoo Finance

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation  Yahoo Finance

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer  PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan

IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent  Stock Titan

IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets  PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

Click here to get full coverage on Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial  Stock Titan

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor  PR Newswire

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors  PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024  PR Newswire

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC  PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PR Newswire

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance  PR Newswire

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PR Newswire

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer  PR Newswire

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth? - simplywall.st

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?  simplywall.st

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth? - simplywall.st

Click here to get full coverage on IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss - Yahoo Finance

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss  Yahoo Finance

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss - Yahoo Finance

Click here to get full coverage on IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen  PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen - PR Newswire

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen  PR Newswire

IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen - PR Newswire

Click here to get full coverage on IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development - Stock Titan

IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development  Stock Titan

IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development - Stock Titan

Click here to get full coverage on IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PR Newswire

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma  PR Newswire

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences  Stock Titan

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan

Click here to get full coverage on IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers  PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PR Newswire

Click here to get full coverage on Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha

Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA)  Seeking Alpha

Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha

Click here to get full coverage on IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PR Newswire

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024  PR Newswire

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform - Yahoo Finance

IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform  Yahoo Finance

IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform - Yahoo Finance

Click here to get full coverage on IDEAYA Announces Pricing of Public Offering - PR Newswire

IDEAYA Announces Pricing of Public Offering  PR Newswire

IDEAYA Announces Pricing of Public Offering - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  Quantisnow

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

Click here to get full coverage on IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer  PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors  PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PR Newswire

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor  PR Newswire

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer  PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PR Newswire

Click here to get full coverage on (IDYA) Trading Report - news.stocktradersdaily.com

(IDYA) Trading Report  news.stocktradersdaily.com

(IDYA) Trading Report - news.stocktradersdaily.com

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events – Company Announcement - Financial Times

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events – Company Announcement  Financial Times

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events – Company Announcement - Financial Times

Click here to get full coverage on Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later  Seeking Alpha

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Click here to get full coverage on Where are the Opportunities in (IDYA) - news.stocktradersdaily.com

Where are the Opportunities in (IDYA)  news.stocktradersdaily.com

Where are the Opportunities in (IDYA) - news.stocktradersdaily.com

Click here to get full coverage on IDEAYA Biosciences to Present at Major Healthcare Investment Conferences - Stock Titan

IDEAYA Biosciences to Present at Major Healthcare Investment Conferences  Stock Titan

IDEAYA Biosciences to Present at Major Healthcare Investment Conferences - Stock Titan

Click here to get full coverage on Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus

Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News  GuruFocus

Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus

Click here to get full coverage on Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming  Seeking Alpha

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha

Click here to get full coverage on IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development - PR Newswire

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development  PR Newswire

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Board Restructuring Plans - TipRanks

IDEAYA Biosciences Announces Board Restructuring Plans  TipRanks

IDEAYA Biosciences Announces Board Restructuring Plans - TipRanks

Click here to get full coverage on Ideaya Biosciences stock hits 52-week low at $16.95 - Investing.com

Ideaya Biosciences stock hits 52-week low at $16.95  Investing.com

Ideaya Biosciences stock hits 52-week low at $16.95 - Investing.com

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - The Malaysian Reserve

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events  The Malaysian Reserve

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - The Malaysian Reserve

Click here to get full coverage on Revolutionary Eye Cancer Drug Achieves FDA Breakthrough Status: 82% Tumor Shrinkage Rate - Stock Titan

Revolutionary Eye Cancer Drug Achieves FDA Breakthrough Status: 82% Tumor Shrinkage Rate  Stock Titan

Revolutionary Eye Cancer Drug Achieves FDA Breakthrough Status: 82% Tumor Shrinkage Rate - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - Financial Times

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events  Financial Times

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - Financial Times

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events – Company Announcement - Financial Times

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events – Company Announcement  Financial Times

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events – Company Announcement - Financial Times

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Financial Times

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  Financial Times

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Financial Times

Click here to get full coverage on IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success - Seeking Alpha

IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success  Seeking Alpha

IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success - Seeking Alpha

Click here to get full coverage on IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - BioSpace

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events  BioSpace

Ideaya Biosciences Inc (IDYA)

Price Chart

Key Statistics

Technicals

About IDYA

Latest News

Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com

IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences - Stock Titan

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

Advanced Charts

Top Gainers

Top Losers